European equities traded in the US as American depositary receipts were advancing on Thursday morning, up 0.5% to 1,346.74 on the S&P Europe Select ADR Index. From continental Europe, the gainers were ...

LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”, the "Company”), a biopharmaceutical company committed to redefining the ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces ...

As 2025 begins, we would like to reflect on last year’s regulatory developments in the biologics and biosimilars space. Here are ...

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target ...

"2024 is expected to be another record-breaking year for ISC as we commenced our mission to double the size of our business by 2028,” said Shawn Peters, President and CEO. "From launching ...

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th - National Comprehensive Cancer Network® adds AUCATZYL® to its Clinical Practice ...

Request To Download Free Sample of This Strategic Report @ The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global CAR T ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its financial results for the ...